Skip to Main Content.
Site navigation
Fidelity.com Home
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log Out
  • Accounts & Trade
    • Portfolio Log In Required
    • Portfolio
    • AccountPositions Log In Required
    • AccountPositions
    • Trade Log In Required
    • Trade
    • Trading Dashboard Log In Required
    • Trading Dashboard Log In Required
    • Active Trader Pro
    • Transfers
    • Cash Management Log In Required
    • Cash Management
    • Bill Pay Log In Required
    • Bill Pay
    • Full View Log In Required
    • Full View
    • Security Settings Log In Required
    • Security Settings
    • Account Features Log In Required
    • Account Features
    • Statements Log In Required
    • Statements
    • Fidelity Alternative Investments Program Log In Required
    • Tax Forms & Information
    • Retirement Distributions Log In Required
    • Fidelity Rewards+registered trademark Log In Required
    • Fidelity Rewards+registered trademark Log In Required
    • New Account Checklist Log In Required
    • Lending Solutions-Line of Credit Log In Required
    • Refer a Friend
  • Planning & Advice
    • What We Offer
    • Build Your Plan
    • My Goals
    • Financial Basics
    • Building Savings
    • Robo Investing Plus Financial Advice
    • Wealth Management
    • Find an advisor
    • Retirement
    • Life Events
    • Saving & Investing for a Child
    • Charitable Giving
    • Philanthropic Consulting
  • News & Research
    • News
    • Wealth Management Insights
    • Watch List Log In Required
    • Quotes
    • Quotes
    • Alerts Log In Required
    • Mutual Funds
    • Stocks
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Markets & Sectors
    • IPOs
    • Annuities
    • Learning Center
    • Notebook
    • Notebook
  • Investment Products
    • Mutual Funds
    • Retirement & IRAs
    • Stocks and Trading
    • Crypto
    • Direct Indexing
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Sustainable Investing
    • Cash Management & Credit Cards
    • Managed Accounts
    • 529 College Savings
    • Health Savings Accounts
    • Annuities
    • Life Insurance & Long Term Care
  • Why Fidelity
    • The Fidelity Advantage
    • Planning & Advice
    • Trading
    • Straightforward Pricing
    • Insights & Tools
    • Security & Protection
    • Marketplace Solutions
    • About Fidelity
    • Careers
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log Out
Content and data provided by various third parties and Fidelity − Terms of Use
  • Research >
  • Stocks >
  • News & Events >

Stock Details


  • Snapshot
  • Detailed Quote
  • Advanced Chart &
    Technical Analysis Opens in New Window
  • News & Events
  • Compare
  • Analyst Opinions
  • Research Reports
  • Key Statistics
  • Earnings
  • Dividends
  • Ownership & Insiders
  • Financial Statements
  • SEC Filings

RELATED RESOURCES

  • Stock Research Overview
  • Stock Screeners
  • Markets & Sectors
  • Fidelity Learning Center Opens in New Window
Print Format
Change Text Size:
  • Default text sizeA
  • Larger text sizeA
  • Largest text sizeA

53 Stocks Moving In Thursday's Mid-Day Session

BY Benzinga
— 12:17 PM ET 06/02/2022

Gainers

  • Repare Therapeutics Inc. NASDAQ:RPTX jumped 38.1% to $12.08 after the company announced it has entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib. Repare will receive a $125 million upfront payment and is eligible to receive up to an additional $1.2 billion in potential milestones.
  • Redbox Entertainment Inc. NASDAQ:RDBX rose 28.1% to $7.18 after declining over 16% on Wednesday.
  • Yumanity Therapeutics, Inc. NASDAQ:YMTX gained 25.3% to $1.4288. Yumanity Therapeutics, last month, posted a Q1 loss of $1.24 per share.
  • Avaya Holdings Corp. NYSE:AVYA jumped 24.4% to $5.30.
  • MDJM Ltd NASDAQ:MDJH gained 24.2% to $2.0494.
  • Immix Biopharma, Inc. NASDAQ:IMMX rose 24.1% to $2.2950 after declining around 14% on Wednesday. Immix Biopharma, last month, announced positive interim data from an animal study in Soft Tissue Sarcoma (STS).
  • American Superconductor Corporation NASDAQ:AMSC gained 23.8% to $6.54 following Q4 results.
  • Missfresh Limited NASDAQ:MF rose 21.6% to $0.2978 after gaining over 51% on Wednesday.
  • electroCore, Inc. NASDAQ:ECOR gained 20.4% to $0.6204.
  • Credo Technology Group Holding Ltd NASDAQ:CRDO gained 20% to $12.30 after the company reported Q4 EPS results up from last year and better-than-expected sales results. The company also issued Q1 sales guidance above analyst estimates.
  • PyroGenesis Canada Inc. NASDAQ:PYR jumped 18.8% to $3.04. PyroGenesis announced project to introduce plasma torches into the upstream anode baking process.
  • Pure Storage, Inc. NYSE:PSTG shares climbed 18.6% to $28.48 after the company reported better-than-expected Q1 financials results. The company also issued Q2 and FY23 sales guidance above analyst estimates.
  • Chewy, Inc. NYSE:CHWY rose 18.5% to $27.85 after the company reported better-than-expected Q1 sales results.
  • Uranium Energy Corp. NYSE:UEC gained 17.6% to $4.1750.
  • MongoDB, Inc. NASDAQ:MDB rose 17.4% to $284.11 after the company reported Q1 EPS results up from last year and better-than-expected sales results. The company also issued Q2 sales guidance above analysts' estimates.
  • Rain Therapeutics Inc. NASDAQ:RAIN jumped 17.2% to $2.86. Roth Capital initiated coverage on Rain Therapeutics with a Buy rating and announced a price target of $16.
  • Dunxin Financial Holdings Limited NYSE:DXF rose 17.2% to $0.58.
  • RISE Education Cayman Ltd NASDAQ:REDU gained 17.1% to $1.64.
  • Integrated Media Technology Limited NASDAQ:IMTE jumped 17% to $9.39.
  • UiPath Inc. NYSE:PATH shares rose 16.1% to $19.54 after the company reported better-than-expected Q1 EPS and sales results. The company also issued Q3 and FY23 sales guidance above analysts' estimates.
  • Gevo, Inc. NASDAQ:GEVO gained 15.8% to $4.7401. Gevo, last month, reported better-than-expected Q1 sales results.
  • MicroVision, Inc. NASDAQ:MVIS jumped 15.6% to $3.9650.
  • Elastic N.V. NYSE:ESTC rose 15.4% to $71.50 after the company reported better-than-expected Q4 EPS and sales results.
  • KE Holdings Inc. NYSE:BEKE gained 15.1% to $14.58. KE Holdings recently announced better-than-expected Q1 sales results.
  • Onconova Therapeutics, Inc. NASDAQ:ONTX surged 14.9% to $1.3101.
  • Lands' End, Inc. NASDAQ:LE jumped 14.7% to $12.78 after the company reported better-than-expected Q1 EPS results.
  • Pineapple Energy Inc. NASDAQ:PEGY jumped 14.4% to $2.39.
  • Veeva Systems Inc. NYSE:VEEV surged 14% to $191.36 after the company reported better-than-expected Q1 EPS and sales results. The company also issued Q2 and FY22 EPS guidance above analysts estimates.
  • comScore, Inc. NASDAQ:SCOR gained 13.9% to $2.21. comScore Director Paul William Livek acquired a total of 600,000 shares at an average price of $1.92.
  • Bright Green Corporation NASDAQ:BGXX gained 13.3% to $4.0101 after dropping 30% on Wednesday.
  • Blue Apron Holdings, Inc. NYSE:APRN rose 9.7% to $3.3663 after the company announced it will be offering a selection of meal kits without a subscription on Walmart.com.


Losers

  • Zosano Pharma Corporation NASDAQ:ZSAN fell 47.4% to $0.9250 after the company announced it filed a voluntary petition for relief under chapter 11.
  • Immunic, Inc. NASDAQ:IMUX shares dipped 41.2% to $3.47 after the company reported data from its Phase 2 CALDOSE-1 trial of Vidofludimus Calcium did not achieve the primary endpoint.
  • Aeglea BioTherapeutics, Inc. NASDAQ:AGLE dropped 40.1% to $0.8983. Aeglea BioTherapeutics announced the U.S. Food and Drug Administration (FDA) has refused to accept the company's Biologics License Application (BLA) with a Refusal to File (RTF) letter.
  • Centessa Pharmaceuticals plc NASDAQ:CNTA fell 20% to $3.60 after the company announced it has made a strategic decision to discontinue development of lixivaptan for Autosomal Dominant Polycystic Kidney Disease including both the Phase 3 ACTION study and the open-label ALERT study.
  • WiSA Technologies, Inc. NASDAQ:WISA declined 19.4% to $0.6456.
  • CASI Pharmaceuticals, Inc. NASDAQ:CASI fell 17% to $3.3740 following effect of 1:10 reverse stock split.
  • CN Energy Group. Inc. NASDAQ:CNEY dropped 15.6% to $1.73.
  • Innovid Corp. NYSE:CTV fell 15.4% to $2.9950.
  • Concert Pharmaceuticals, Inc. NASDAQ:CNCE shares declined 14.9% to $4.56 after the company priced its common stock offering of 10 million shares at $4.75 per share.
  • Midatech Pharma plc NASDAQ:MTP dropped 14.7% to $0.64. The U.S. Food and Drug Administration (FDA) recently granted Fast Track Designation to Midatech Pharma PLC's NASDAQ:MTP lead drug candidate MTX110 for the treatment of patients with recurrent glioblastoma (rGBM).
  • Acorda Therapeutics, Inc. NASDAQ:ACOR fell 14.6% to $0.38.
  • Limelight Networks, Inc. NASDAQ:LLNW declined 13.9% to $2.9950.
  • Energy Focus, Inc. NASDAQ:EFOI fell 13.5% to $1.0550 after jumping 37% on Wednesday.
  • Lightwave Logic, Inc. NASDAQ:LWLG dropped 12.4% to $6.95.
  • Mullen Automotive, Inc. NASDAQ:MULN fell 11.5% to $1.2550. Mullen Automotive recently announced results of its solid-state polymer battery testing with the Battery Innovation Center in Indiana.
  • Advanced Human Imaging Limited NASDAQ:AHI dropped 11.1% to $0.7225.
  • Histogen Inc. NASDAQ:HSTO shares fell 10.7% to $0.14. Histogen reported a 1-for-20 reverse stock split.
  • Nutex Health, Inc. NASDAQ:NUTX fell 10.5% to $9.64.
  • Enjoy Technology, Inc. NASDAQ:ENJY dropped 10.2% to $0.2563.
  • C3.ai, Inc. NYSE:AI shares fell 9.8% to $16.73 after the company issued Q1 and FY23 sales guidance below analyst estimates.
  • Conn's, Inc. NASDAQ:CONN dropped 9.2% to $11.38. The company reported mixed results for its first quarter.
  • Hewlett Packard Enterprise Company NYSE:HPE fell 6.6% to $14.75 after the company reported worse-than-expected Q2 financials results. The company also issued Q3 and FY22 EPS guidance with midpoints below analyst estimates.

More ESTC News

  • BRIEF-Elastic Reports Strong Fourth Quarter And Fiscal 2022 Financial Results
    Reuters - 4:14 PM ET 06/01/2022
  • Elastic Reports Strong Fourth Quarter and Fiscal 2022 Financial Results
    Business Wire - 4:05 PM ET 06/01/2022
  • Earnings Scheduled For June 1, 2022
    Benzinga - 4:49 AM ET 06/01/2022
Fidelity Investments. Copyright 1998–2022 FMR LLC. 
All rights reserved. 

  • Terms of Use|
  • Privacy|
  • Security|
  • Site Map 
Close